Dana McClintock

Chief Medical Officer at Vasomune Therapeutics

Dr. McClintock is the Chief Medical Officer of Alladapt Immunotherapeutics, Inc., a role she has held since 2018. Prior to joining Alladapt, Dr. McClintock was Global Head of Innovation for Immunology, Infectious Disease and Ophthalmology, at Genentech/Roche. Prior to this position, Dr. McClintock held roles of increasing responsibility at Genentech/Roche, including Global Head of Pipeline and Portfolio Planning for Immunology, Infectious Disease and Ophthalmology, as well as Interim Global Co-Head of Ophthalmology. Earlier in Dr. McClintock’s pharmaceutical career, she was deeply involved in respiratory, immunology and ophthalmology clinical development activities across a range of phases, from IND-enabling work and early clinical trials through post-marketing commitments and medical affairs activities. Dr. McClintock was involved in key clinical development activities for omalizumab (Xolair) and ranibizumab (Lucentis) as along with other pipeline molecules. Prior to joining the pharmaceutical industry, Dr. McClintock’s academic research focus was in ARDS, with publications evaluating ventilator parameters as well plasma biomarkers of epithelial and endothelial cell injury. Dr. McClintock received a BA in Chemistry from Duke University and an MD from the University of Virginia. Dr. McClintock completed her training in Internal Medicine and Pulmonary and Critical Care Medicine, both at the UCSF.

Timeline

  • Chief Medical Officer

    Current role